Atlas Trials

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Clinical trial NCT03288454 · COMPLETED

Trial details

NCT number
NCT03288454
Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Healthy
Start date
2017-08-30
Primary completion
2019-08-05
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.